Moderna (NASDAQ:MRNA) Shares Gap Down – What’s Next?

Moderna, Inc. (NASDAQ:MRNA)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $31.92, but opened at $30.53. Moderna shares last traded at $32.53, with a volume of 7,862,619 shares changing hands.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research report on Monday, November 18th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Piper Sandler reissued an “overweight” rating and issued a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research report on Monday, November 18th. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Finally, Evercore ISI dropped their price target on shares of Moderna from $60.00 to $50.00 and set an “in-line” rating for the company in a research report on Monday, January 27th. Four equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Moderna currently has an average rating of “Hold” and an average price target of $66.89.

Moderna Stock Up 3.3 %

The firm has a market capitalization of $12.69 billion, a PE ratio of -5.66 and a beta of 1.59. The firm’s 50 day moving average price is $39.31 and its two-hundred day moving average price is $55.94. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MRNA. Exchange Traded Concepts LLC boosted its stake in Moderna by 164.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 17,558 shares of the company’s stock valued at $1,173,000 after acquiring an additional 10,907 shares during the last quarter. Swedbank AB boosted its stake in Moderna by 149.6% during the 3rd quarter. Swedbank AB now owns 85,099 shares of the company’s stock valued at $5,687,000 after acquiring an additional 51,000 shares during the last quarter. Vontobel Holding Ltd. boosted its stake in Moderna by 148.2% during the 3rd quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock valued at $7,758,000 after acquiring an additional 69,313 shares during the last quarter. Paragon Capital Management Inc. raised its holdings in shares of Moderna by 97.4% during the third quarter. Paragon Capital Management Inc. now owns 10,007 shares of the company’s stock worth $669,000 after purchasing an additional 4,937 shares during the period. Finally, Probity Advisors Inc. raised its holdings in shares of Moderna by 15.8% during the third quarter. Probity Advisors Inc. now owns 4,844 shares of the company’s stock worth $324,000 after purchasing an additional 661 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.